Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Market Closed - Nasdaq Other stock markets 01:30:00 12/07/2025 am IST			5-day change	1st Jan Change
18.17 ^USD	-4.69%		-0.38%	-85.06%

01/07	Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell Midcap Value Index	CI
01/07	Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 3000 Value Index	CI

Sarepta Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08:40 AM

Published on 15/05/2025 at 02:00

Presenter Speech
Tazeen Ahmad (Analysts)

And here at the Bank of America Healthcare Conference, I'm Tazeen Ahmad. I'm one of the senior SMid biotech analysts at the firm. It's my pleasure to have our

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell Midcap Value Index	01/07	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 3000 Value Index	01/07	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 2500 Value Index	30/06	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 1000 Value Index	30/06	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell Small Cap Comp Value Index	30/06	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 3000E Value Index	30/06	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell Midcap Value Benchmark	30/06	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 2500 Value Benchmark	30/06	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 3000 Value Benchmark	30/06	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell Small Cap Comp Value Benchmark	30/06	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 3000E Value Benchmark	30/06	CI
Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 1000 Value Benchmark	30/06	CI
Sarepta Therapeutics' Elevidys Under Investigation by US FDA Following Patient Deaths	25/06	MT
FDA investigates patient deaths after treatment with Sarepta's gene therapy	25/06	RE
FDA investigates patient deaths after treatment with Sarepta's gene therapy	25/06	RE
Sector Update: Health Care Stocks Retreat Late Afternoon	21/06	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	20/06	MT
Sarepta Therapeutics Shares Decline After Downgrade From William Blair	20/06	MT
The Two-Week Ticking Clock	20/06
William Blair Downgrades Sarepta Therapeutics to Market Perform From Outperform	20/06	MT
Analyst recommendations: Apple, Dow, Coinbase, Comcast, The Gap…	20/06
Goldman Sachs Downgrades Sarepta Therapeutics to Neutral From Buy, Adjusts Price Target to $29 From $100	18/06	MT
TD Cowen Downgrades Sarepta Therapeutics to Hold From Buy, Cuts Price Target to $24 From $62	18/06	MT
A Rate Decision in a War Drumbeat	18/06
Analysts recommendations: Sarepta Therapeutics, Broadcom, Enphase Energy, Lam Research…	18/06